Abstract
Partly due to lack of detailed knowledge of the molecular recognition of ligands the structural basis for partial versus full agonism is not known. In the β2-adrenergic receptor the agonist binding site has previously been structurally and functionally exchanged with an activating metal-ion site located between AspIII:08—or a His residue introduced at this position in transmembrane domain (TM)-III—and a Cys residue substituted for AsnVII:06 in TM-VII. Here, this interhelical, bidentate metal-ion site is without loss of Zn2+ affinity transferred to the tachykinin NK1receptor. In contrast to the similarly mutated β2-adrenergic receptor, signal transduction—i.e., inositol phosphate turnover—could be stimulated by both Zn2+ and by the natural agonist, Substance P in the mutated NK1 receptor. The metal-ion acted as a 25% partial agonist through binding to the bidentate zinc switch located exactly one helical turn below the two previously identified interaction points for Substance P in, respectively, TM-III and -VII. The metal-ion chelator, phenantroline, which in the β2-adrenergic receptor increased both the potency and the agonistic efficacy of Zn2+ or Cu2+ in complex with the chelator, also bound to the metal-ion site-engineered NK1 receptor, but here the metal-ion chelator complex instead acted as a pure antagonist. It is concluded that signaling of even distantly related rhodopsin-like 7TM receptors can be activated through Zn2+ coordination between metal-ion binding residues located at positions III:08 and VII:06. It is suggested that only partial agonism is obtained through this simple well defined metal-ion coordination due to lack of proper interactions with residues also in TM-VI.
Footnotes
- Received January 19, 2000.
- Accepted May 11, 2000.
-
Send reprint requests to: Dr. Thue W. Schwartz, Laboratory for Molecular Pharmacology, Department of Pharmacology, The Panum Institute, Building 18.6, Blegdamsvej 3, DK-2200, Copenhagen, Denmark. E-mail: schwartz{at}molpharm.dk
-
This study was supported by grants from the Biotechnology Center for Molecular Recognition through the Danish Medical and Science Research Council as well as grants from the Carlsberg and Lundbeck foundations. B.H. was supported by grants from P. Carl Petersens Foundation.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|